⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 1, 2024Journal of Clinical Oncology

Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.

View Full Paper

Ask AI

Bookmark

Share

Authors

JSJoseph M. ScanduraCornell University AGAaron T. GerdsCleveland Clinic EREllen K. RitchieCornell University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Scandura et al. (2024) studied this question.

synapsesocial.com/papers/68e66db4b6db6435875f86ad https://doi.org/10.1200/jco.2024.42.16_suppl.tps6593

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.2024 · 2 citations
2Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study2026 · 5 citations
3Selinexor Plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis: Phase 3 SENTRY Trial2026 · 2 citations
4Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics2025
5Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial.2026